datopotamab deruxtecan
Sponsor Astrazeneca PLC · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-09-30
As disclosedSep 30, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06417814
PhasePHASE3
StatusRECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)Metastatic Non-small Cell Lung Cancer
All tracked catalysts for datopotamab deruxtecan
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-09-30 | READOUT | medium | NCT06417814 |
| 2027-06-30 | READOUT | medium | NCT06564844 |
| 2027-07-28 | READOUT | medium | NCT06103864 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More AZN catalysts